Neurocrine wins FDA nod for CAH therapy

Sedang Trending 1 bulan yang lalu
  • Healthcare
Headquarters of US Food and Drug Administration (FDA)

Grandbrothers

  • Neurocrine Biosciences (NASDAQ:NBIX) has received FDA support for Crenessity (crinecerfont) arsenic a shape of curen for adults and children pinch classical congenital adrenal hyperplasia (CAH), a uncommon hormonal disorder.
  • The San Diego, California-based biotech announced precocious Friday that Crenessity has become

Recommended For You

More Trending News

See More »

Selengkapnya
Sumber 1
1